<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892043</url>
  </required_header>
  <id_info>
    <org_study_id>SQZ-AAC-HPV-101</org_study_id>
    <nct_id>NCT04892043</nct_id>
  </id_info>
  <brief_title>Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SQZ Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SQZ Biotechnologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic&#xD;
      effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in&#xD;
      combination with immune checkpoint inhibitors in HLA-A*02+ patients with recurrent, locally&#xD;
      advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The&#xD;
      study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or&#xD;
      vaginal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events according to NCI CTCAE version 5.0</measure>
    <time_frame>Up to 1 year after LPFV (Last Patient, First Visit)</time_frame>
    <description>To determine the RP2D and to characterize the safety and tolerability of SQZ-AAC-HPV administered as monotherapy (Part 1), and in combination with checkpoint inhibitors (Part 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size compared with baseline using RECIST 1.1 and iRECIST</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>To determine antitumor activity (Part 1 and 2) of SQZ-AAC-HPV monotherapy and in combination with checkpoint inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of potential doses from individual patient blood collection</measure>
    <time_frame>Up to 3 months after LPFV</time_frame>
    <description>To determine manufacturing feasibility (Part 1 only)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in cytokine levels compared with baseline</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>To explore changes in blood cytokines after treatment with SQZ-AAC-HPV (Part 1 and 2)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in T cell infiltration in the tumor micro-environment as assessed by paired biopsy</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>To characterize the immunogenic and pharmacodynamic effects (on selected pharmacodynamic parameters) and duration of pharmacodynamic response following SQZ-AAC-HPV administration (Part 1 and 2)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Adult Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 Monotherapy Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, SQZ-AAC-HPV as a monotherapy is administered every 3 weeks for up to a year.&#xD;
There are 3 groups (&quot;Cohorts&quot;) in this Phase as follows:&#xD;
Cohort 1a: low dose SQZ-AAC-HPV&#xD;
Cohort 1b: intermediate dose SQZ-AAC-HPV&#xD;
Cohort 1c: high dose SQZ-AAC-HPV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, SQZ-AAC-HPV in combination with immune checkpoint inhibitors (1) ipilimumab, (2) nivolumab, or (3) nivolumab plus ipilimumab is administered every 3 weeks up to a year, but the immune checkpoint inhibitors may be administered up to 2 years. There are 3 groups (&quot;Cohorts&quot;) in this Phase as follows:&#xD;
Cohort 2a: SQZ-AAC-HPV RP2D (Recommended Phase 2 Dose) plus ipilimumab&#xD;
Cohort 2b: SQZ-AAC-HPV RP2D plus nivolumab&#xD;
Cohort 2c: SQZ-AAC-HPV RP2D plus nivolumab and ipilimumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SQZ-AAC-HPV</intervention_name>
    <description>activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16</description>
    <arm_group_label>Part 1 Monotherapy Dose Escalation Phase</arm_group_label>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody</description>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>programmed cell death 1 (PD-1) blocking antibody</description>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients â‰¥18 years of age who are HLA-A*02+&#xD;
&#xD;
          -  Histologically confirmed incurable or metastatic solid tumors that are HPV16+&#xD;
&#xD;
          -  Cancer must have progressed after at least 1 available standard therapy for incurable&#xD;
             disease, or the patient is intolerant to or refuses standard therapy(ies) or has a&#xD;
             tumor for which no standard therapy(ies) exist&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1&#xD;
&#xD;
          -  At least 1 measurable lesion according to RECIST 1.1&#xD;
&#xD;
          -  Must have a lesion that can be biopsied with acceptable clinical risk and agree to&#xD;
             have a fresh biopsy at Baseline and on Cycle 2 Day 8 (+/- 3 days)&#xD;
&#xD;
          -  Patients must agree to venous access for the blood draw and be willing to have a&#xD;
             central line inserted if venous access is an issue&#xD;
&#xD;
          -  Adequate organ function and bone marrow reserve performed within 14 days prior to the&#xD;
             blood draw&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with anticancer therapy, including investigational therapy, within 2 weeks&#xD;
             prior to blood draw. For prior therapies with a half-life longer than 3 days,&#xD;
             discontinuation of the therapy must have occurred at least 28 days prior to Cycle 1&#xD;
             Day 1&#xD;
&#xD;
          -  Systemic treatment with either corticosteroids (&gt;10 mg of prednisone or the equivalent&#xD;
             per day) or other immunosuppressive medications within 14 days prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Patients treated with non-corticosteroid based immunosuppressive agents within the&#xD;
             last 6 months may not be eligible and should be discussed with the Sponsor&#xD;
&#xD;
          -  Patients with active, known, or suspected autoimmune disease may not be eligible and&#xD;
             should be discussed with the Sponsor&#xD;
&#xD;
          -  Patients with &gt;Grade 1 AEs related to previous treatment with anticancer or&#xD;
             investigational therapy that do not resolve at least 2 weeks prior to blood draw,&#xD;
             except Grade 2 alopecia&#xD;
&#xD;
          -  Known active hepatitis B or hepatitis C, or active mycobacterium tuberculosis&#xD;
             infection&#xD;
&#xD;
          -  History of any Grade 4 immune-related AE (irAE) from prior immunotherapy&#xD;
&#xD;
          -  Has known active central nervous system metastases&#xD;
&#xD;
          -  History of interstitial lung disease requiring steroids&#xD;
&#xD;
          -  Significant acute or chronic illness&#xD;
&#xD;
          -  Major surgery within 2 weeks of blood draw&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ricardo F. Zwirtes, MD</last_name>
    <phone>203-506-7253</phone>
    <email>AAC-HPV-101@sqzbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Guido</last_name>
      <phone>858-534-0254</phone>
      <email>jeguido@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Sandip Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>cancer</keyword>
  <keyword>cervical</keyword>
  <keyword>head and neck</keyword>
  <keyword>anal</keyword>
  <keyword>penile</keyword>
  <keyword>SQZ-AAC-HPV</keyword>
  <keyword>HPV16</keyword>
  <keyword>AAC</keyword>
  <keyword>cell therapy</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>nivolumab</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>solid tumor</keyword>
  <keyword>HLA-A*02</keyword>
  <keyword>therapeutic vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

